SCANCELL HOLDINGS PLC: Scope 2 melanoma trial beats milestones
September 23, 2023Scancell’s Phase 2 SCOPE trial for advanced melanoma impressed – with Initial data from 11 patients showing an 82% objective…Internal note – SCANCELL HOLDINGS PLC: Multiple Arrows in its Quiver
April 17, 2023Scancell is an early-stage bio-technology company that is well positioned with 4 distinct technology platforms, in the high-growth immuno-oncology space.…